Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.

Sonneveld P, Zweegman S, Facon T, Hungria V, Bahlis NJ, Moreau P, Einsele H, Boccadoro M, Borgsten F, Borsi A, Nobrega M, Kovács V, Wang J, Rowe M, Sitthi-Amorn A, Carson RL, Dimopoulos MA, Rodríguez-Otero P, Usmani SZ

Open source

DOI: 10.1200/jco-26-00384
Published: 2026 Nov 9
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00384,
  title = {Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.},
  author = {Sonneveld P and Zweegman S and Facon T and Hungria V and Bahlis NJ and Moreau P and Einsele H and Boccadoro M and Borgsten F and Borsi A and Nobrega M and Kovács V and Wang J and Rowe M and Sitthi-Amorn A and Carson RL and Dimopoulos MA and Rodríguez-Otero P and Usmani SZ},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-26-00384},
  url = {https://doi.org/10.1200/jco-26-00384}
}

RIS

TY  - JOUR
TI  - Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.
AU  - Sonneveld P
AU  - Zweegman S
AU  - Facon T
AU  - Hungria V
AU  - Bahlis NJ
AU  - Moreau P
AU  - Einsele H
AU  - Boccadoro M
AU  - Borgsten F
AU  - Borsi A
AU  - Nobrega M
AU  - Kovács V
AU  - Wang J
AU  - Rowe M
AU  - Sitthi-Amorn A
AU  - Carson RL
AU  - Dimopoulos MA
AU  - Rodríguez-Otero P
AU  - Usmani SZ
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-26-00384
UR  - https://doi.org/10.1200/jco-26-00384
ER  -

APA

P, S., S, Z., T, F., V, H., NJ, B., P, M., H, E., M, B., F, B., A, B., M, N., V, K., J, W., M, R., A, S., RL, C., MA, D., P, R., & SZ, U. (2026). Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-26-00384

Source records

pubmed · retrieved 2026-11-10T11:17:58.310Z